US equities
|
SPCX
$167.29
▲+5.24%
NVDA
$236.34
▲+1.02%
MU
$1,064.49
▼-0.97%
TSLA
$378.22
▲+2.06%
MSFT
$525.50
▲+1.54%
SNDK
$1,708.31
▼-0.68%
INTC
$117.36
▼-1.65%
META
$744.62
▲+2.27%
SPCX
$167.29
▲+5.24%
NVDA
$236.34
▲+1.02%
MU
$1,064.49
▼-0.97%
TSLA
$378.22
▲+2.06%
MSFT
$525.50
▲+1.54%
SNDK
$1,708.31
▼-0.68%
INTC
$117.36
▼-1.65%
META
$744.62
▲+2.27%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Achilles Therapeutics PLC
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
May 22, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
ARCT
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 08, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
April 04, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
April 04, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
February 05, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
December 18, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
November 13, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 04, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics to Present at Upcoming Conferences
June 12, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 10, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
May 10, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
April 25, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
April 25, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
April 17, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights
March 07, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
December 06, 2022
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
November 30, 2022
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
November 22, 2022
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 08, 2022
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
October 06, 2022
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Tickers
ACHL
